Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Total Current Liabilities (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Total Current Liabilities data on record, last reported at $62.1 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities changed N/A year-over-year to $62.1 million; the TTM value through Sep 2025 reached $62.1 million, changed N/A, while the annual FY2024 figure was $45.0 million, 12.77% down from the prior year.
  • Total Current Liabilities reached $62.1 million in Q3 2025 per GOSS's latest filing, up from $53.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $62.1 million in Q3 2025 and bottomed at $40.1 million in Q2 2023.
  • Average Total Current Liabilities over 4 years is $47.9 million, with a median of $46.7 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: dropped 19.62% in 2023, then increased 18.61% in 2025.
  • A 4-year view of Total Current Liabilities shows it stood at $49.2 million in 2022, then increased by 4.81% to $51.6 million in 2023, then fell by 12.77% to $45.0 million in 2024, then skyrocketed by 38.01% to $62.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $62.1 million in Q3 2025, $53.6 million in Q2 2025, and $48.2 million in Q1 2025.